McIlrath & Eck’s Jazz Pharmaceuticals JAZZ Stock Holding History

McIlrath & Eck’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-172	Closed	-$21.4K	–	955
2025 Q1	$21.4K	Hold	172	–	–	﹤0.01%	470
2024 Q4	$21.2K	Hold	172	–	–	﹤0.01%	474
2024 Q3	$19.2K	Buy	172 +33	+24%	+$3.62K	﹤0.01%	477
2024 Q2	$14.8K	Buy	139 +19	+16%	+$2.09K	﹤0.01%	520
2024 Q1	$14.4K	Hold	120	–	–	﹤0.01%	536
2023 Q4	$14.8K	Sell	120 -2	-2%	-$250	﹤0.01%	472
2023 Q3	$15.8K	Hold	122	–	–	﹤0.01%	444
2023 Q2	$15.1K	Hold	122	–	–	﹤0.01%	469
2023 Q1	$17.9K	Hold	122	–	–	﹤0.01%	433
2022 Q4	$19.4K	Hold	122	–	–	0.01%	415
2022 Q3	$16K	Hold	122	–	–	﹤0.01%	442
2022 Q2	$19K	Sell	122 -3	-2%	-$462	0.01%	393
2022 Q1	$19K	Hold	125	–	–	0.01%	408
2021 Q4	$16K	Hold	125	–	–	﹤0.01%	452
2021 Q3	$16K	Hold	125	–	–	﹤0.01%	438
2021 Q2	$22K	Buy	125 +3	+2%	+$520	0.01%	370
2021 Q1	$20K	Buy	+122	New	+$20.1K	0.01%	342

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

McIlrath & Eck's JAZZ Position: Q2 2025 in Review

McIlrath & Eck sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2025, closing a stake of 172 shares — an estimated $21.4K sold.

McIlrath & Eck first reported a position in JAZZ in Q1 2021 and held it in 17 quarters. The position peaked at $22K in Q2 2021. 502 funds tracked by Wall St. Rank hold JAZZ as of Q2 2025.

McIlrath & Eck reported no remaining Jazz Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
McIlrath & Eck sold 172 Jazz Pharmaceuticals shares in Q2 2025, an estimated $21.4K.
McIlrath & Eck first reported a position in Jazz Pharmaceuticals in Q1 2021 and held it in 17 quarters.
McIlrath & Eck's Jazz Pharmaceuticals position peaked at $22K in Q2 2021.
502 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2025.

Based on McIlrath & Eck's 13F filing for Q2 2025, filed 14 Aug 2025.